Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review
You may also be interested in...
On The Horizon: Planned Filings For Novel Drugs In 2011
On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.
On The Horizon: Planned Filings For Novel Drugs In 2011
On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.
On The Horizon: Planned Filings For Novel Drugs In 2011
On top of the full slate of pending applications, the pool of potential novel product approvals in 2011 continues to grow as more submissions come in.